¼¼°èÀÇ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ½ÃÀå
Bioequivalence Studies
»óǰÄÚµå : 1777852
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 385 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ½ÃÀåÀº 2030³â±îÁö 11¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 7¾ï 5,930¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 11¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀúºÐÀÚ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀº CAGR 8.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 1,530¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ëÇü ºÐÀÚ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 2¾ï 690¸¸ ´Þ·¯, Áß±¹Àº CAGR 10.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ½ÃÀåÀº 2024³â¿¡ 2¾ï 690¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³â°£ CAGR 10.8%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 2¾ï 3,550¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.2%¿Í 6.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.4%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¦³×¸¯ ÀǾàǰ °³¹ß¿¡¼­ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÌ ¿Ö Áß¿äÇѰ¡?

»ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀº Á¦¾à »ê¾÷, ƯÈ÷ Á¦³×¸¯ ÀǾàǰÀÇ °³¹ß ¹× ½ÂÀο¡ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¿¬±¸¿¡¼­´Â Á¦³×¸¯ ÀǾàǰÀÌ ¿À¸®Áö³Î ÀǾàǰ°ú µ¿ÀÏÇÑ ¾àµ¿ÇÐÀû Ư¼º(Èí¼ö, ºÐÆ÷, ´ë»ç, ¹è¼³)À» º¸ÀÌ´ÂÁö ¿©ºÎ¸¦ Æò°¡ÇÕ´Ï´Ù. ¹Ì±¹ FDA, À¯·´ÀǾàǰû(EMA), ±âŸ ¼¼°è º¸°Ç´ç±¹ µî ±ÔÁ¦±â°üÀº Á¦³×¸¯ ÀǾàǰÀÌ Çõ½Å ÀǾàǰ°ú µ¿ÀÏÇÑ Ä¡·á È¿°ú, ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, »ýü ÀÌ¿ë·üÀ» Á¦°øÇϵµ·Ï º¸ÀåÇϱâ À§ÇØ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀ» Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ ÇコÄɾ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÇ´Â °¡¿îµ¥, Á¦¾à»çµéÀº °íǰÁúÀÇ Á¦³×¸¯ ÀǾàǰÀ» ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇØ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÐ¼® ±â¼ú°ú °è»ê ¸ðµ¨¸µÀÇ ¹ßÀüÀ¸·Î »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ¾î Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷üÀÇ ±ÔÁ¦ ´ç±¹ ½ÂÀΰú ½ÃÀå ÁøÀÔÀÌ »¡¶óÁö°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Àú·ÅÇÑ Ä¡·áÁ¦¸¦ ã´Â °¡¿îµ¥, »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀº ÀǾàǰ Çõ½Å°ú Á¢±Ù¼ºÀ» À§ÇÑ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÇ È¿À²¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

¾àµ¿ÇÐ ¹× ÀÓ»ó ¿¬±¸ ºÐ¾ßÀÇ ´«ºÎ½Å ±â¼ú ¹ßÀüÀº »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ Á¤È®¼º, È¿À²¼º ¹× ºñ¿ë È¿À²¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ÷´Ü ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ-Áú·® ºÐ¼®(LC-MS) ±â¼úÀÇ ÅëÇÕÀ¸·Î ¾à¹° ³óµµ ÃøÁ¤ÀÇ ¹Î°¨µµ¿Í Á¤È®µµ°¡ Çâ»óµÇ¾î º¸´Ù È®½ÇÇÑ »ýü ÀÌ¿ë·ü Æò°¡°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, »ý¸®Àû ¾àµ¿ÇÐ(PBPK) ¸ðµ¨¸µ°ú in silico ½Ã¹Ä·¹À̼ÇÀ» ÅëÇØ Àΰ£ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í, ±ÔÁ¦ Áؼö¸¦ À¯ÁöÇϸ鼭 ÀǾàǰ °³¹ß ÀÏÁ¤À» °£¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû µ¿µî¼º ¿¬±¸ÀÇ ¶Ç ´Ù¸¥ ºñ¾àÀûÀÎ ¹ßÀüÀº ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®°ú ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» Àû¿ëÇÏ¿© ¾àµ¿ÇÐÀû °Åµ¿À» Á¶±â¿¡ ¿¹ÃøÇϰí Á¦Á¦ °£ ÀáÀçÀû Â÷À̸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ±â¼ú Çõ½ÅÀº º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ½ÂÀÎÀ» ¿ëÀÌÇÏ°Ô Çϰí, »ý¹°ÇÐÀû µ¿µî¼ºÀÇ ¹üÀ§¸¦ ±âÁ¸ÀÇ ÀúºÐÀÚ Á¦³×¸¯ ÀǾàǰ ¿ÜÀÇ ´Ù¸¥ ÀǾàǰÀ¸·Î È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸ ¹æ¹ýÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀº ´õ¿í ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç, ÁøÈ­ÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿¡ ÀûÀÀÇÒ ¼ö ÀÖ¾î Á¦³×¸¯°ú ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÌ ÃÖ°í ¼öÁØÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» ÃæÁ·ÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ½ÃÀå µ¿ÇâÀº ¹«¾ùÀΰ¡?

¸î °¡Áö ÁÖ¿ä ½ÃÀå µ¿ÇâÀÌ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÇ È®´ë¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ÀÌ´Â Àú·ÅÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ±ÔÁ¦ Á¶È­ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀÌ ¿À¸®Áö³Î ÀǾàǰÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ¸·Î Àü ¼¼°èÀûÀ¸·Î ¹Þ¾Æµé¿©Áö¸é¼­, ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè¿¡ ´ëÇÑ ¿ä±¸»çÇ×ÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ±â°üÀº ¿©·¯ °üÇұǿ¡¼­ »ý¹°ÇÐÀû µ¿µî¼º °¡À̵å¶óÀÎÀ» Ç¥ÁØÈ­ÇÏ¿© ¿©·¯ Áö¿ª¿¡¼­ µ¿½Ã¿¡ ÀǾàǰÀ» ½ÂÀÎÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, Á¦¾à»ç ½ÃÀå ÁøÀÔ À庮ÀÌ ³·¾ÆÁ³½À´Ï´Ù. ¶ÇÇÑ, ÈíÀÔÄ¡·áÁ¦, Á¡¾ÈÁ¦, °æÇÇÈí¼öÆÐÄ¡ µî º¹ÀâÇÑ Á¦³×¸¯ ÀǾàǰ Áõ°¡·Î ÀÎÇØ º¸´Ù Á¤±³ÇÑ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ¼³°èÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀ» Àü¹®À¸·Î ÇÏ´Â ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)ÀÇ ±Þ¼ÓÇÑ È®´ëµµ ´«¿¡ ¶ç´Â Ãß¼¼À̸ç, ÀÌ´Â Á¦¾à±â¾÷ÀÌ ¿î¿µºñ¿ëÀ» Àý°¨Çϰí ÇÙ½É ÀǾàǰ °³¹ß¿¡ ÁýÁßÇϱâ À§ÇØ ÀÓ»ó½ÃÇè ¾Æ¿ô¼Ò½ÌÀ» ¿ä±¸Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ºÐ»êÇü ÀÓ»ó½ÃÇè(DCT)°ú µðÁöÅÐ Çコ ±â¼úÀÇ µµÀÔÀ¸·Î »ý¹°ÇÐÀû µ¿µî¼º ¿¬±¸°¡ Çö´ëÈ­µÇ°í ȯÀÚ ¸ðÁý, ÄÄÇöóÀ̾ð½º, ½ÇÁ¦ µ¥ÀÌÅÍ ¼öÁýÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¼¼°è Á¦¾à »ê¾÷ÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀº ÀǾàǰ ½ÂÀÎ ¹× ½ÃÀå È®´ë Àü·«ÀÇ ±âº» ¿ä¼Ò·Î ³²À» °ÍÀÔ´Ï´Ù.

»ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

»ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀº Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­, ÀÓ»ó½ÃÇè ¹æ¹ýÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °í¼öÀÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á´Â Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, ½ÃÀå ½ÂÀÎÀ» º¸ÀåÇϱâ À§ÇØ Á¾ÇÕÀûÀÎ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÌ »ý¹°ÇÐÀû µ¿µî¼º µ¥ÀÌÅÍ¿¡ ´ëÇØ ´õ¿í ¾ö°ÝÇÑ ÄÄÇöóÀ̾𽺠¿ä°ÇÀ» ºÎ°úÇÔ¿¡ µû¶ó, Á¦¾à»çµéÀº ÷´Ü ¿¬±¸ ¹æ¹ýÀ» äÅÃÇϰí, °íÁ¤¹Ð ºÐ¼® µµ±¸¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. CRO¿¡ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀ» ¾Æ¿ô¼Ò½ÌÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, Á¦¾à»ç´Â ÀÚ¿øÀ» ÃÖÀûÈ­Çϸ鼭 ÀǾàǰ °³¹ßÀ» ½Å¼ÓÇÏ°Ô ÁøÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Çʿ伺À¸·Î ÀÎÇØ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, °íºÐÀÚ ÀǾàǰ¿¡ ´ëÇÑ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àεµ, Áß±¹, ºê¶óÁú µî ½ÅÈï ½ÃÀå¿¡¼­´Â Á¦³×¸¯ ÀǾàǰ »ê¾÷ÀÌ ¼ºÀåÇÏ°í ±ÔÁ¦°¡ ±¹Á¦ ±âÁØ¿¡ ºÎÇÕÇϱ⠶§¹®¿¡ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ °æÁ¦¼º°ú ±â¼ú Çõ½ÅÀÇ ±ÕÇüÀ» ¸ÂÃß±â À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥, »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇèÀº ÀǾàǰÀÇ Á¢±Ù¼º°ú ºñ¿ë Àý°¨À» °¡´ÉÇÏ°Ô ÇÏ´Â Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

ºÐÀÚ À¯Çü(ÀúºÐÀÚ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè, °íºÐÀÚ »ý¹°ÇÐÀû µ¿µî¼º ½ÃÇè), Á¦Çü(°íÇü °æ±¸Á¦, ºñ°æ±¸Á¦, ¿Ü¿ëÁ¦, ±âŸ Á¦Çü), Ä¡·á ¿µ¿ª(¾Ï Ä¡·á ¿µ¿ª, ½Å°æ Ä¡·á ¿µ¿ª, ¸é¿ª Ä¡·á ¿µ¿ª, ´ë»çÀå¾Ö Ä¡·á ¿µ¿ª, Ç÷¾× Ä¡·á ¿µ¿ª, ±âŸ Ä¡·á ¿µ¿ª)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bioequivalence Studies Market to Reach US$1.1 Billion by 2030

The global market for Bioequivalence Studies estimated at US$759.3 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Small Molecule Bioequivalence Studies, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$615.3 Million by the end of the analysis period. Growth in the Large Molecule Bioequivalence Studies segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$206.9 Million While China is Forecast to Grow at 10.8% CAGR

The Bioequivalence Studies market in the U.S. is estimated at US$206.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$235.5 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Bioequivalence Studies Market - Key Trends & Drivers Summarized

Why Are Bioequivalence Studies Critical in Generic Drug Development?

Bioequivalence studies play an essential role in the pharmaceutical industry, particularly in the development and approval of generic drugs. These studies evaluate whether a generic version of a drug demonstrates the same pharmacokinetic properties-absorption, distribution, metabolism, and excretion-as its branded counterpart. Regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), and other global health authorities mandate bioequivalence studies to ensure that generic medications provide the same therapeutic effect, safety profile, and bioavailability as innovator drugs. With the growing emphasis on cost-effective healthcare and the increasing expiration of patents on blockbuster drugs, pharmaceutical companies are investing heavily in bioequivalence testing to bring high-quality generics to market. Additionally, advancements in analytical technologies and computational modeling are improving the precision and efficiency of bioequivalence studies, facilitating faster regulatory approvals and market entry for generic drug manufacturers. As healthcare systems worldwide seek affordable treatment alternatives, bioequivalence studies remain a cornerstone of pharmaceutical innovation and accessibility.

How Are Technological Advancements Enhancing the Efficiency of Bioequivalence Testing?

Significant technological advancements in pharmacokinetics and clinical research are revolutionizing bioequivalence studies, improving their accuracy, efficiency, and cost-effectiveness. The integration of advanced liquid chromatography-mass spectrometry (LC-MS) techniques has enhanced the sensitivity and precision of drug concentration measurements, allowing for more robust bioavailability assessments. Additionally, the adoption of physiologically based pharmacokinetic (PBPK) modeling and in silico simulations is reducing the reliance on human clinical trials, streamlining drug development timelines while maintaining regulatory compliance. Another breakthrough in bioequivalence research is the application of real-time data analytics and machine learning algorithms, enabling early prediction of pharmacokinetic behavior and identifying potential variability between formulations. Moreover, innovations in biosimilar bioequivalence studies are facilitating the approval of complex biologic drugs, expanding the scope of bioequivalence beyond traditional small-molecule generics. With continuous advancements in study methodologies, bioequivalence testing is becoming faster, more reliable, and more adaptable to evolving regulatory frameworks, ensuring that generic and biosimilar drugs meet the highest standards of safety and efficacy.

What Market Trends Are Driving the Growth of Bioequivalence Studies?

Several key market trends are influencing the expansion of bioequivalence studies, reflecting the growing demand for affordable pharmaceuticals and regulatory harmonization efforts. The increasing global acceptance of generics as a cost-effective alternative to branded drugs has led to a surge in bioequivalence testing requirements, particularly in emerging markets. Regulatory agencies are standardizing bioequivalence guidelines across multiple jurisdictions, allowing for simultaneous drug approvals in multiple regions and reducing market entry barriers for pharmaceutical companies. Additionally, the rise of complex generics, including inhalation therapies, ophthalmic solutions, and transdermal patches, is driving the need for more sophisticated bioequivalence study designs. The rapid expansion of contract research organizations (CROs) specializing in bioequivalence testing is another prominent trend, as pharmaceutical firms seek to outsource clinical trials to reduce operational costs and focus on core drug development. Furthermore, the growing adoption of decentralized clinical trials (DCTs) and digital health technologies is modernizing bioequivalence research, improving patient recruitment, compliance, and real-world data collection. As the global pharmaceutical industry continues to evolve, bioequivalence studies will remain a fundamental component of drug approval and market expansion strategies.

What Are the Key Factors Fueling the Growth of the Bioequivalence Studies Market?

The growth in the bioequivalence studies market is driven by several factors, including the rising demand for generic drugs, increasing regulatory scrutiny, and advancements in clinical trial methodologies. The expiration of patents on high-revenue pharmaceutical products is creating a lucrative opportunity for generic drug manufacturers, necessitating comprehensive bioequivalence studies to ensure market approval. Additionally, regulatory agencies are imposing stricter compliance requirements on bioequivalence data, prompting pharmaceutical companies to adopt advanced testing methodologies and invest in high-precision analytical tools. The outsourcing of bioequivalence studies to CROs is also accelerating market growth, allowing pharmaceutical firms to expedite drug development while optimizing resources. The expanding biosimilars market, driven by the need for cost-effective biologic therapies, is further fueling demand for bioequivalence studies tailored to large-molecule drugs. Moreover, emerging markets such as India, China, and Brazil are witnessing a surge in bioequivalence testing due to their growing generic pharmaceutical industries and regulatory alignment with international standards. As healthcare systems worldwide strive to balance affordability and innovation, bioequivalence studies will continue to be a vital enabler of pharmaceutical accessibility and cost reduction.

SCOPE OF STUDY:

The report analyzes the Bioequivalence Studies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Molecule Type (Small Molecule Bioequivalence Studies, Large Molecule Bioequivalence Studies); Dosage Form (Solid Oral Dosage, Parenteral Formulations, Topical Products, Other Dosage Forms); Therapeutic Area (Oncology Therapeutic Area, Neurology Therapeutic Area, Immunology Therapeutic Area, Metabolic Disorders Therapeutic Area, Hematology Therapeutic Area, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â